New Delhi: The Technical Advisory Group (TAG) of WHO had recommended Emergency Use Listing (EUL) status for Bharat Biotech’s Covaxin, the PTI reported.
The WHO is in the process of evaluating Covaxin’s clinical trial data for use of EUL.
The panel had earlier sought additional clarifications from the manufacturer of Covaxin to conduct a final EUL risk-benefit assessment for global use of the vaccine.
The TAG is an independent advisory group that recommends WHO on whether a vaccine can be listed for emergency use under the EUL procedure.
Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.
It is one of the six vaccines that have received emergency use authorisation from India’s drug regulator and is being used in the nationwide inoculation programme, along with Covishield and Sputnik V.
